No results for ‘’
Nectar Lifescience Ltd
₹11.44
(1.63%)
Sat, 20 Jun 2026, 03:09 pm
Health Technology
Pharmaceuticals: Major
24.5KNectar Lifescience Return on Equity (ROE) History
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 9.47 | 6.50 | 5.59 | 4.45 | 8.44 | 5.20 | 7.35 | 4.10 | 8.74 | 12.51 | 15.70 | 14.25 | 11.35 | 8.06 | 6.98 | 0 | 21.53 | 0 | 135.20 | 0 |
| Price to book ratio | 1.99 | 0.97 | 1.08 | 0.57 | 1.31 | 0.74 | 0.69 | 0.40 | 0.59 | 0.86 | 0.89 | 0.78 | 0 | 0.35 | 0.20 | 0.39 | 0.50 | 0.33 | 0.63 | 0.54 |
| Price to sales ratio | 1.39 | 0.68 | 0.57 | 0.32 | 0.93 | 0.51 | 0.41 | 0.22 | 0.33 | 0.50 | 0.51 | 0.48 | 0.32 | 0.14 | 0.09 | 0.27 | 0.32 | 0.23 | 0.40 | 0.31 |
| Price to cash flow ratio | 0 | 45.65 | 2.78 | 2.25 | 0 | 0 | 7.20 | 1.34 | 4.22 | 21.39 | 16.66 | 8.96 | 0 | 3.95 | 1.37 | 0 | 29.83 | 6.36 | 4.50 | 5.35 |
| Enterprise value | 498Cr | 681Cr | 877Cr | 905Cr | 1351Cr | 1299Cr | 1556Cr | 1224Cr | 1391Cr | 1718Cr | 1777Cr | 1654Cr | 1538Cr | 1265Cr | 979Cr | 1295Cr | 1381Cr | 1092Cr | 1290Cr | 1078Cr |
| Enterprise value to EBITDA ratio | 8.18 | 8.42 | 6.92 | 6.40 | 6.88 | 5.80 | 6.79 | 4.22 | 4.83 | 6.46 | 7.40 | 7.32 | 6.46 | 4.74 | 4.41 | 11.62 | 8.67 | 19.84 | 8.35 | 0 |
| Debt to equity ratio | 0.84 | 1.91 | 1.71 | 2.32 | 0.97 | 1.10 | 1.33 | 1.01 | 0.93 | 0.97 | 1.01 | 0.87 | 0.90 | 0.82 | 0.69 | 0.85 | 0.79 | 0.71 | 0.59 | 0.61 |
| Return on equity % | 28.26 | 21.69 | 29.61 | 18.04 | 19.98 | 15.37 | 9.73 | 10.38 | 6.92 | 7.03 | 5.67 | 5.64 | 5.06 | 4.40 | 2.84 | -6.67 | 2.33 | -2.25 | 0.47 | -11.23 |
Nectar Lifescience Ltd Return on Equity
The Nectar Lifescience Ltd Return on Equity is a key financial metric used by investors to evaluate Nectar Lifescience Ltd's valuation, profitability, and overall financial performance. Tracking the Nectar Lifescience Ltd Return on Equity helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Nectar Lifescience Ltd (NSE: NECLIFE, BSE: 532649) is currently trading at ₹11.44, with a market capitalization of ₹223.4Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Nectar Lifescience Ltd Return on Equity is essential for fundamental analysis.
Nectar Lifescience Ltd Return on Equity Current Value
The current Nectar Lifescience Ltd Return on Equity stands at -11.23.
The Nectar Lifescience Ltd Return on Equity has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Nectar Lifescience Ltd Return on Equity Historical Trend
The Nectar Lifescience Ltd Return on Equity has shown the following historical trend:
- 2024: -11.23
- 2023: 0.47
- 2022: -2.25
- 2021: 2.33
- 2020: -6.67
The decline in Nectar Lifescience Ltd Return on Equity indicates improving financial efficiency or better earnings growth.
What Nectar Lifescience Ltd Return on Equity Indicates for Investors
The Nectar Lifescience Ltd Return on Equity plays a crucial role in understanding the company's financial health and valuation.
ROE indicates how efficiently the company generates returns for shareholders.
Nectar Lifescience Ltd Return on Equity Analysis Summary
The Nectar Lifescience Ltd Return on Equity remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Nectar Lifescience Ltd Return on Equity should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Nectar Lifescience Ltd Return on Equity helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.